Data / Form D filings / Aktis Oncology, Inc.
Aktis Oncology, Inc.: Form D filing
Aktis Oncology, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2024. The latest, on October 2, 2024, reports $175 million sold of a $175 million offering to 39 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 17 DRYDOCK AVENUE, SUITE #17-401, Boston, MA, 02210
- Phone
- (978) 237-4380
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2035832
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2024 | New notice | $175,000,000 | $175,000,000 | 39 | Sep 20, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Helen S. Kim | Director | |
| Shulamit S. Ron-Bigger | Executive Officer | |
| Ken S. Herrmann | Director | |
| Lloyd S. Segal | Director | |
| Oleg Nodelman | Director | |
| Andrew S. Levin | Director | |
| Matthew Roden | Executive Officer, Director | |
| Todd Foley | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Sep 30, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Aktis Oncology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.